Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

Anaerobe

Volumn 41, Issue , 2016, Pages 58-67

  Kaleko, Michael ^a   Bristol, J Andrew ^a   Hubert, Steven ^a   Parsley, Todd ^b   Widmer, Giovanni ^c   Tzipori, Saul ^c   Subramanian, Poorani ^d   Hasan, Nur ^d   Koski, Perrti ^e   Kokai Kun, John ^a   Sliman, Joseph ^a   Jones, Annie ^a   Connelly, Sheila ^a  

^a Synthetic Biologics   (United States)

^b SynPhaGen LLC   (United States)

^c TUFTS UNIVERSITY   (United States)

^d Research and Development Department   (United States)

^e Ipsat Therapies   (Finland)

Author keywords

Antibiotic risk factors; Beta lactamase; Clostridium difficile; Healthcare associated infections; Microbiome

Indexed keywords

AMOXICILLIN; AMPICILLIN; BETA LACTAMASE; CEFAZOLIN; CEFOPERAZONE; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; PIPERACILLIN; SYN 004; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; RECOMBINANT PROTEIN; SYN-004;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOG; DRUG DEGRADATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TRACT; INFECTION PREVENTION; INTESTINE FLORA; NONHUMAN; PIG; PRIORITY JOURNAL; ANIMAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMAN; KINETICS; MICROBIAL SENSITIVITY TEST; PEPTOCLOSTRIDIUM DIFFICILE; PH;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CLOSTRIDIUM DIFFICILE; DOGS; DRUG RESISTANCE, BACTERIAL; DRUG STABILITY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL MICROBIOME; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MICROBIAL SENSITIVITY TESTS; RECOMBINANT PROTEINS; SUS SCROFA;

EID: 84973524678     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2016.05.015     Document Type: Article

References (55)

1. [1] Cenit, M.C., Matzaraki, V., Tigchelaar, E.F., Zhernakova, A., Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim. Biophys. Acta 1842 (2014), 1981–1992, 10.1016/j.bbadis.2014.05.023.
2. [2] Sommer, F., Backhed, F., The gut microbiota–masters of host development and physiology. Nat. Rev. Microbiol. 11 (2013), 227–238, 10.1038/nrmicro2974.
3. [3] Guinane, C.M., Cotter, P.D., Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Ther. Adv. Gastroenterol. 6 (2013), 295–308, 10.1177/1756283x13482996.
4. [4] Kamada, N., Seo, S.U., Chen, G.Y., Nunez, G., Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13 (2013), 321–335, 10.1038/nri3430.
5. [5] West, C.E., Renz, H., Jenmalm, M.C., Kozyrskyj, A.L., et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. J. Allergy Clin. Immunol. 135 (2015), 3–13, 10.1016/j.jaci.2014.11.012 quiz 14.
6. [6] Britton, R.A., Young, V.B., Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146 (2014), 1547–1553, 10.1053/j.gastro.2014.01.059.
7. [7] Crowther, G.S., Wilcox, M.H., Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm. Infect. Drug Resist 8 (2015), 333–337, 10.2147/IDR.S87224.
8. [8] Guggenbichler, J.P., Allerberger, F.J., Dierich, M., Influence of cephalosporins III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatr. Padol. 21 (1986), 335–342.
9. [9] Guggenbichler, J.P., Kofler, J., Allerberger, F., The influence of third-generation cephalosporins on the aerobic intestinal flora. Infection 13:Suppl 1 (1985), S137–S139.
10. [10] Rice, L.B., Antimicrobial resistance in gram-positive bacteria. Am. J. Med. 119 (2006), S11–S19, 10.1016/j.amjmed.2006.03.012 discussion S62-70.
11. [11] Arlington Medical Resources, Audits of Acute Care Hospital Antibiotic Utilization. 2014.
12. [12] Vesteinsdottir, I., Gudlaugsdottir, S., Einarsdottir, R., Kalaitzakis, E., et al. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 31 (2012), 2601–2610, 10.1007/s10096-012-1603-0.
13. [13] Goldberg, E.J., Bhalodia, S., Jacob, S., Patel, H., et al. Clostridium difficile infection: a brief update on emerging therapies. Am. J. Health Syst. Pharm. 72 (2015), 1007–1012, 10.2146/ajhp140645.
14. [14] Spector, T., Knight, R., Faecal transplants. BMJ, 351, 2015, h5149, 10.1136/bmj.h5149.
15. [15] Weil, A.A., Hohmann, E.L., Fecal microbiota transplant: benefits and risks. Open Forum Infect. Dis., 2, 2015, 10.1093/ofid/ofv005.
16. [16] Wilke, M.S., Lovering, A.L., Strynadka, N.C., Beta-lactam antibiotic resistance: a current structural perspective. Curr. Opin. Microbiol. 8 (2005), 525–533, 10.1016/j.mib.2005.08.016.
17. [17] Neugebauer, K., Sprengel, R., Schaller, H., Penicillinase from Bacillus licheniformis: nucleotide sequence of the gene and implications for the biosynthesis of a secretory protein in a Gram-positive bacterium. Nucleic Acids Res. 9 (1981), 2577–2588.
18. [18] Tarkkanen, A.M., Heinonen, T., Jogi, R., Mentula, S., et al. P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin. Antimicrob. Agents Chemother. 53 (2009), 2455–2462.
19. [19] Pitout, J.D., IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr. Opin. Investig. Drugs 10 (2009), 838–844, 10.1128/AAC.00853-08.
20. [20] Stiefel, U., Nerandzic, M.M., Koski, P., Donskey, C.J., Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J. Antimicrob. Chemother. 62 (2008), 1105–1108, 10.1093/jac/dkn298.
21. [21] Stiefel, U., Pultz, N.J., Harmoinen, J., Koski, P., et al. Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice. J. Infect. Dis. 188 (2003), 1605–1609, 10.1086/379153.
22. [22] Harmoinen, J., Vaali, K., Koski, P., Syrjanen, K., et al. Enzymic degradation of a beta-lactam antibiotic, ampicillin, in the gut: a novel treatment modality. J. Antimicrob. Chemother. 51 (2003), 361–365.
23. [23] Harmoinen, J., Vaali, K., Lindevall, K., Heino, P., Westermarck, E., A novel therapy in prevention of antibiotic-induced changes in faecal microflora. Int. J. Antimicro Agents, 19, 2002, S67.
24. [24] Harmoinen, J., Mentula, S., Heikkila, M., van der Rest, M., et al. Orally administered targeted recombinant beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance. Antimicrob. Agents Chemother. 48 (2004), 75–79.
25. [25] A Study of SYN-004 for the prevention of C. diff in patients with a LRTI. Clinicaltrials.gov, NCT02563106. accessed 16.05.16.
26. [26] Kokai-Kun, J.F., Bristol, J.A., Setser, J., Schlosser, M., Nonclinical safety assessment of SYN-004: an oral b-lactamase for the protection of the gut microbiome from disruption by biliary-excreted, intravenously administered antibiotics. Int. J. Toxicol. 35 (2016), 309–316.
27. [27] Hanes, C.S., Studies on plant amylases: the effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley. Biochem. J. 26 (1932), 1406–1421.
28. [28] Jones, R.N., Wilson, H.W., Novick, W.J. Jr., Barry, A.L., Thornsberry, C., In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent. J. Clin. Microbiol. 15 (1982), 954–958.
29. [29] Zhang, Q., Widmer, G., Tzipori, S., A pig model of the human gastrointestinal tract. Gut Microbes 4 (2014), 193–200.
30. [30] Tzipori, S., Rand, W., Griffiths, J., Widmer, G., Crabb, J., Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diagn. Lab. Immunol. 1 (1994), 450–463.
31. [31] Hasan, N.A., Young, B.A., Minard-Smith, A.T., Saeed, K., et al. Microbial community profiling of human saliva using shotgun metagenomic sequencing. PLoS One, 9, 2014, e97699, 10.1371/journal.pone.0097699.
32. [32] Lax, S., Smith, D.P., Hampton-Marcell, J., Owens, S.M., et al. Longitudinal analysis of microbial interaction between humans and the indoor environment. Science 345 (2014), 1048–1052, 10.1126/science.1254529.
33. [33] Gaujoux, R., Seoighe, C., A flexible R package for nonnegative matrix factorization. BMC Bioinforma., 11, 2010, 367.
34. [34] Tibshirani, R., Hastie, T., Narasimhan, B., Chu, G., Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 6567–6572, 10.1073/pnas.082099299.
35. [35] Ambler, R.P., Coulson, A.F., Frere, J.M., Ghuysen, J.M., et al. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276:Pt 1 (1991), 269–270.
36. [36] Kaleko, M., Bristol, J.A., Parsely, T., Connelly, S., Koski, P., SYN-004, a Class A b-Lactamase Therapy for the Prevention of Antibiotic-induced Disruption of Intestinal Microflora._ID Week, Philadelphia, PA. 2014 Abstract 270.
37. [37] Connelly, S., Widmer, G., Mukherjee, J., Huynh, K., et al. SYN-004, a Clinical Stage Oral Beta-lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-mediated Damage in Humanized Pigs. 2015, Digestive Diseases Week, Washington, DC Abstract 2054.
38. [38] Connelly, S., Widmer, G., Subramanian, P., Bristol, J.A., et al. A Clinical Stage Oral Beta-lactamase Therapy Prevents Antibiotic-mediated Damage of the Gut Microbiome. 2015, International Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA Slide Session 151.
39. [39] Pimentel, M., Gunsalus, R.P., Roa, S.S., Zhang, H., Methanogens in human health and disease. Am. J. Gastroenterol. 1:Supp. (2002), 28–33.
40. [40] Minamoto, Y., Otoni, C.C., Steelman, S.M., Buyukleblebici, O., et al. Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut Microbes 6 (2015), 33–47, 10.1080/19490976.2014.997612.
41. [41] Rossi, G., Pengo, G., Caldin, M., Palumbo Piccionello, A., et al. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS One, 9, 2014, e94699, 10.1371/journal.pone.0094699.
42. [42] Slimings, C., Riley, T.V., Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J. Antimicrob. Chemother. 69 (2014), 881–891.
43. [43] Wilcox, M.H., Freeman, J., Fawley, W., MacKinlay, S., Brown, A., Donaldson, K., Corrado, O., Long-term surveillance of cefotaxime and pipercillin-taxobactam prescribing and incidence of Clostridium difficile Diarrhoea. J. Antimicrob. Chemother. 54 (2004), 168–172.
44. [44] Alston, W.K., Ahern, J.W., Increase in the rate of nosocomial clostridium difficile-associated diarrhea during shortages of piperacillin-taxobactam and piperacillin. J. Antimicrob. Chemother. 53 (2004), 549–550.
45. [45] Dubberke, E.R., Reske, K.A., Seiler, S., Hink, T., Kwon, J.H., Burnham, C.-A.D., Risk factors for acquisition and loss of Clostridium difficile colonization in hospitalized patients. Antimicrob. Agents Chemother. 59 (2015), 4533–4543.
46. [46] Stiefel, U., Harmoinen, J., Koski, P., Kaariainen, S., et al. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice. Antimicrob. Agents Chemother. 49 (2005), 5190–5191, 10.1128/AAC.49.12.5190-5191.2005.
47. [47] Sliman, J., Bristol, J.A., Hubert, S., Couglin, O., et al. Clinical Evaluation of SYN-004, An Oral Beta-lactamase Therapy for the Prevention of Antibiotic-induced Disruption of Intestinal Microflora. 2015, American Society of Microbiology, New Orleans, LA Abstract 953.
48. [48] Kokai-Kun, J., A novel strategy to protect the gut microbiome from the deleterious effects of residual IV β-lactam antibiotics. J. Int. Soc. Microbiota, 1, 2015, 41.
49. [49] Kokai-Kun, J., Bristol, J.A., Setser, J., Schlosser, M., Nonclinical safety assessment of SYN-004: an oral β-Lactamase for the protection of the gut microbiome form disruption by biliary-excreted, intravenously-administered antibiotics. J. Toxicol., 2016 in press.
50. [50] Stevens, V., Dumyati, G., Fine, L.S., Fisher, S.G., van Wijngaarden, E., Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin. Infect. Dis. 53 (2011), 42–48.
51. [51] Khoder, M., Taspis, N., Domergue-Dupont, V., Gueutin, C., Fattal, E., Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. Eur. J. Pharm. Sci. 41 (2010), 281–288.
52. [52] Nguyen, T.T., Chachaty, E., Huy, C., Cambier, C., de Gunzburg, J., Mentre, F., Andremont, A., Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant enterobacteriaceae in piglets treated with ciprofloxacin: toward new means to control the spread of resistance?. Antimicrob. Agents Chemother. 56 (2012), 4973–4975.
53. [53] Stass, H., Kubitza, D., Moller, J.G., Delesen, H., Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br. J. Clin. Pharmacol. 59 (2005), 536–541.
54. [54] Connelly, S., Parsely, T., Koski, P., Kaleko, M., Development of Therapeutic Agents that Protect the Colonic Microflora from All Beta-lactam Antibiotics for the Prevention of Clostridium difficile Infection. 2015, American Society of Microbiology General Meeting, New Orleans, LA Abstract 201.
55. [55] Kaleko, M., Bristol, J.A., Connelly, S., Koski, P., P4A, a Novel Oral Beta-lactamase for the Prevention of Cephalosporin-induced C. difficile Infection. 2014, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society of Microbiology, Washington, DC Abstract F-250c.